772
P A R T 8
Drugs acting on the cardiovascular system
BIBLIOGRAPHY
Chapman, N. H., Brighton, T., Harris, M., Caplan, G. A.,
Braithwaite, J. (2009). Venous thromboembolism: management in
general practice.
Australian Family Physician, 38(1–2)
, 36–40.
Farrell, M. & Dempsey, J. (2014).
Smeltzer & Bare’s Textbook of
Medical-Surgical Nursing
(3rd edn). Sydney: Lippincott Williams
& Wilkins.
Goodman, L. S., Brunton, L. L., Chabner, B. & Knollmann, B. C.
(2011).
Goodman and Gilman’s Pharmacological Basis of
Therapeutics
(12th edn). New York: McGraw-Hill.
Hassan, S. S., Feng, S. R., Ahmadi, K., Ahmad, K. M.,
Chong, D. W. K., Anwar, M. & Badarudin, N. Z. (2010). Factors
influencing concomitant use of complementary and alternative
medicines with warfarin.
Journal of Pharmacy Practice &
Research, 40(4)
, 294–299.
Hicks, R. W., Wanzer, L. J. & Goeckner, B. (2011). Perioperative
pharmacology: Blood coagulation modifiers.
AORN Journal,
93(6)
, 726–736.
Ho, W. K. (2010). Deep vein thrombosis: Risks and diagnosis.
Australian Family Physician, 39(7)
, 468–474.
Lankshear, A., Harden, J. & Simms, J. (2010). Safe practice for
patients receiving anticoagulant therapy.
Nursing Standard,
24(20)
, 47–56.
Leung, E. S., Hamilton-Bruce, M. A. & Koblar, S. A. (2010).
Warfarin: indications, risks and drug interactions.
Australian
Family Physician, 39(11)
, 820–824.
Lowinger, J. S. & Maxwell, D. J. (2009). Heparins for venous
thromboembolism prophylaxis—safety issues.
Australian
Prescriber, 32(4)
, 108–112.
McKenna, L. (2012).
Pharmacology Made Incredibly Easy
(1st Australian and New Zealand edn). Sydney: Lippincott
Williams & Wilkins.
McKenna, L. & Mirkov, S. (2014).
McKenna’s Drug Handbook for
Nursing and Midwifery
(7th edn). Sydney: Lippincott Williams
& Wilkins.
McRae, S. (2010). Pulmonary embolism.
Australian Family
Physician, 39(7)
, 462–466.
Merriman, E. (2011). Antiplatelet drugs, anticoagulants and elective
surgery.
Australian Prescriber, 34(5)
, 139–143.
Myers, S. P. (2002). Interactions between complementary medicines
and warfarin.
Australian Prescriber, 25
, 54–56.
Nguyen, T., Yacoub, M., Chan, T-I. & Quach, K. (2012). Atrial
fibrillation: Focus on anticoagulant pharmacotherapy.
Journal
for Nurse Practitioners, 8(7)
, 560–565.
Nutescu, E. A. (2013). Oral anticoagulant therapies: Balancing the
risks.
American Journal of Health-System Pharmacy, 70(10)
,
S3–S11.
Pickering, A. & Thomas, D. P. (2007). An audit of INR control in
the Australian indigenous setting.
Australian Family Physician,
36(11)
, 959–969.
Porth, C. M. (2011).
Essentials of Pathophysiology: Concepts
of Altered Health States
(3rd edn). Philadelphia: Lippincott
Williams & Wilkins.
Porth, C. M. (2009).
Pathophysiology: Concepts of Altered Health
States
(8th edn). Philadelphia: Lippincott Williams & Wilkins.
Samardhi, H. (2011). Current management of atrial fibrillation.
Australian Prescriber, 34(4)
, 100–104.
Tadros, R. & Shakib, S. (2010). Clot prevention: Common questions
about medications.
Australian Family Physician, 39(7)
,
480–483.
Tadros, R. & Shakib, S. (2010). Warfarin: indications, risks and
drug interactions.
Australian Family Physician, 39(7)
, 476–479.
C H E C K Y O U R U N D E R S T A N D I N G
Answers to the questions in this chapter can be found in
Appendix A at the back of this book.
MULTIPLE CHOICE
Select the best answer to the following.
1.
Blood coagulation is a complex reaction that
involves:
a.
vasoconstriction, platelet aggregation and
plasminogen action.
b.
vasodilation, platelet aggregation and activation
of the clotting cascade.
c.
vasoconstriction, platelet aggregation and
conversion of prothrombin to thrombin.
d.
vasodilation, platelet inhibition, and action of the
intrinsic and extrinsic clotting cascades.
2.
Warfarin, an oral anticoagulant, acts:
a.
to directly prevent the conversion of prothrombin
to thrombin.
b.
to decrease the production of vitamin K clotting
factors in the liver.
c.
as a catalyst in the conversion of plasminogen to
plasmin.
d.
immediately, so it is the drug of choice in
emergency situations.
3.
Heparin reacts to prevent the conversion of
prothrombin to thrombin. Heparin:
a.
is available in oral and parenteral forms.
b.
takes about 72 hours to have a therapeutic effect.
c.
has its effects reversed with the administration of
protamine sulfate.
d.
has its effects reversed with the injection of
vitamin K.
